In a mouse model of APP/PS1 mice, besides inhibiting NLRP3-dependent symptoms seen in Alzheimer’s disease, MCC950 also increased the uptake of β-amyloid plaques and ameliorated neurological outcomes by inducing their clearance (Dempsey et al., 2017). Here, APP is linked to Alzheimer disease.